Atom Bioscience completes RMB150m in Series B financing

Atom Bioscience recently completed a 150 million RMB B round of financing, from Kaitai Capital and Livzon Pharmaceutical Group.

Atom Bioscience recently completed a 150 million RMB B round of financing, from Kaitai Capital and Livzon Pharmaceutical Group.

Atom Bioscience is a new drug developer of anti-on?? tumor and metabolic diseases, mainly engaged in the research and development of new drugs for the treatment of diabetes, gout and anti-tumor. Among them, many innovative drugs have entered the preclinical research stage, and 2 of them have independent intellectual property rights and are being prepared for sales.

The core team of the company is mainly from the United States and has extensive experience in developing innovative drugs. The CEO of the company, Dr. Shi Dongfang, has been engaged in the research and development of first-in-class innovative drugs such as anti-tumor, anti-HCV, and treatment of type 2 diabetes in the United States and Britain for 20 years before returning to China.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/03/atom-bioscience-completes-rmb150m-in-series-b-financing/.

Leave a Reply

Please Login to Comment